Gastrointestinal stromal tumors (GISTs) are the most common malignant subepithelial
lesions (SELs) of the gastrointestinal tract. They originate from the interstitial cells of Cajal …

Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the
commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as …

The value of any new therapeutic strategy or treatment is determined by the magnitude of its
clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment …

Background Until now, only imatinib and sunitinib have proven clinical benefit in patients
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Background The ATLAS trial compared axitinib versus placebo in patients with locoregional
renal cell carcinoma (RCC) at risk of recurrence after nephrectomy. Patients and methods In …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since it is …

Importance Adjuvant imatinib is associated with improved recurrence-free survival (RFS)
when administered after surgery to patients with operable gastrointestinal stromal tumor …

Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib …

Background Adjuvant sunitinib significantly improved disease-free survival (DFS) versus
placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence …